Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.
2/5 보강
OpenAlex 토픽 ·
Colorectal Cancer Screening and Detection
Genetic factors in colorectal cancer
Global Cancer Incidence and Screening
[INTRODUCTION] Colorectal cancer (CRC) screening remains below national targets among US women.
- 표본수 (n) 114,360
APA
Mallik Greene, Leobon Gameng, et al. (2026). Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.. Advances in therapy. https://doi.org/10.1007/s12325-026-03590-8
MLA
Mallik Greene, et al.. "Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.." Advances in therapy, 2026.
PMID
41984312 ↗
Abstract 한글 요약
[INTRODUCTION] Colorectal cancer (CRC) screening remains below national targets among US women. Primary care providers (PCPs) play an important role in promoting CRC screening adherence. Many US women see an obstetrician/gynecologist (OB/GYN) as their PCP. We evaluated adherence among US women to multi-target stool DNA (mt-sDNA) testing and follow-up colonoscopy ordered by OB/GYNs.
[METHODS] We linked Exact Sciences Laboratories (ESL) orders with a national multi-payer claims database (2016-2022). Eligible participants were average-risk women aged 45-75 years with continuous health plan enrollment (- 180 to 0 days baseline; 0-365 days to assess mt-sDNA adherence; and, after a positive mt-sDNA result, 0-365 days to assess colonoscopy). Primary outcomes were mt-sDNA completion within 365 days of kit shipment and colonoscopy completion within 365 days of a positive mt-sDNA test. Logistic regression evaluated factors associated with mt-sDNA adherence.
[RESULTS] Of 160,068 women with OB/GYN-ordered mt-sDNA, 71.4% (n = 114,360/160,068) completed testing within 365 days. Test positivity was 8.6% (n = 9773/114,360). Among those with positive results, 71.3% (n = 6971/9773) completed colonoscopy within 365 days. Test adherence increased with age (45-49 years, 67.1%; 50-64 years, 71.8%; 65-75 years, 76.7%), was higher in non-metropolitan areas, and rose with higher ZIP code median household income. Test adherence was higher among individuals with traditional Medicare (85.2%) and Medicare Advantage (77.3%) than commercial insurance (71.3%) and Medicaid (61.7%).
[CONCLUSION] In routine practice, more than 70% of women completed OB/GYN-ordered mt-sDNA testing and, after a positive result, more than 70% completed colonoscopy within 1 year. OB/GYN clinicians may play a key role in improving CRC screening adherence, with opportunities to address gaps by payer, income, and race/ethnicity.
[METHODS] We linked Exact Sciences Laboratories (ESL) orders with a national multi-payer claims database (2016-2022). Eligible participants were average-risk women aged 45-75 years with continuous health plan enrollment (- 180 to 0 days baseline; 0-365 days to assess mt-sDNA adherence; and, after a positive mt-sDNA result, 0-365 days to assess colonoscopy). Primary outcomes were mt-sDNA completion within 365 days of kit shipment and colonoscopy completion within 365 days of a positive mt-sDNA test. Logistic regression evaluated factors associated with mt-sDNA adherence.
[RESULTS] Of 160,068 women with OB/GYN-ordered mt-sDNA, 71.4% (n = 114,360/160,068) completed testing within 365 days. Test positivity was 8.6% (n = 9773/114,360). Among those with positive results, 71.3% (n = 6971/9773) completed colonoscopy within 365 days. Test adherence increased with age (45-49 years, 67.1%; 50-64 years, 71.8%; 65-75 years, 76.7%), was higher in non-metropolitan areas, and rose with higher ZIP code median household income. Test adherence was higher among individuals with traditional Medicare (85.2%) and Medicare Advantage (77.3%) than commercial insurance (71.3%) and Medicaid (61.7%).
[CONCLUSION] In routine practice, more than 70% of women completed OB/GYN-ordered mt-sDNA testing and, after a positive result, more than 70% completed colonoscopy within 1 year. OB/GYN clinicians may play a key role in improving CRC screening adherence, with opportunities to address gaps by payer, income, and race/ethnicity.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Evaluation of Colorectal Cancer Incidence in the United States From 2021 to 2024 Using a National Multi-Payer Claims Database.
- Real-world adherence to multi-target stool DNA testing and its association with time to follow-up colonoscopy: a health-system analysis from Massachusetts General Hospital.
- Adherence to multi-target stool DNA test and time to follow-up colonoscopy: real-world analysis of patients from the Beth Israel Lahey Health.
- Real-World Adherence to Repeat Colorectal Cancer Screening With the Multi-Target Stool DNA Test in a Large, Insured, and Average-Risk Population.
- High Adherence to Repeat Multitarget Stool DNA Testing and Follow-Up Colonoscopy in Average-Risk United States Adults: Results from a Nationally Insured Cohort.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- EXPLORING THE IMPACT OF GUT MICROBIOTA MODULATION ON COLORECTAL CANCER THERAPY: A BIBLIOMETRIC ANALYSIS OF PROBIOTIC AND PREBIOTIC INTERVENTIONS.
- Safe discharge on the second postoperative day after major colorectal surgery: a decision-making strategy based on quantitative serological data.
- System-Wide Implementation of Colorectal Cancer Screening in a Value-Based Care Setting.
- The Increase of Early-Onset Colorectal Cancer: New Insights and Emerging Hypotheses.
- The Centers for Medicare and Medicaid Services and others misunderstand stool testing for colorectal cancer.
- PIBAdb: a public cohort of multimodal colonoscopy videos and images including polyps with histological information.